Ethos Capital Management
ABBV icon

Ethos Capital Management’s AbbVie ABBV Stock Holding History

Ethos Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.02M Buy
11,531
+1,248
+12% +$320K 2.01% 11
2026
Q2 		$2.59M Buy
10,283
+2,756
+37% +$593K 1.84% 16
2026
Q1 		$1.64M Buy
7,527
+1,254
+20% +$278K 1.4% 24
2025
Q4 		$1.43M Buy
+6,273
New +$1.43M 1.35% 30

Other funds holding ABBV

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Ethos Capital Management's ABBV Position: Q3 2026 in Review

Ethos Capital Management increased its AbbVie (ABBV) stake by 12% in Q3 2026, buying an estimated $320K and bringing the position to 11,531 shares worth $3.02M. The position accounts for 2.01% of the portfolio, ranked #11.

Ethos Capital Management first reported a position in ABBV in Q4 2025 and has held it in 4 quarters since. 2,418 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Ethos Capital Management held 11,531 shares of AbbVie worth $3.02M as of Q3 2026.
  • Ethos Capital Management bought 1,248 AbbVie shares in Q3 2026, an estimated $320K.
  • AbbVie made up 2.01% of Ethos Capital Management's portfolio in Q3 2026, its #11 holding.
  • Ethos Capital Management first reported a position in AbbVie in Q4 2025 and has held it in 4 quarters since.
  • 2,418 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Ethos Capital Management's 13F filing for Q3 2026, filed 3 Nov 2026.